Plus Therapeutics (NASDAQ:PSTV) Trading 0.6% Higher – What’s Next?

Plus Therapeutics, Inc. (NASDAQ:PSTV)’s share price shot up 0.6% on Thursday . The stock traded as high as $3.69 and last traded at $3.65. 51,978 shares changed hands during trading, a decline of 57% from the average session volume of 120,239 shares. The stock had previously closed at $3.63.

Analyst Upgrades and Downgrades

A number of research firms recently commented on PSTV. Ascendiant Capital Markets decreased their target price on Plus Therapeutics from $65.00 to $57.00 and set a “buy” rating for the company in a report on Monday, June 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Plus Therapeutics in a research report on Friday, July 17th. Finally, Wall Street Zen raised shares of Plus Therapeutics to a “sell” rating in a report on Saturday, April 4th. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $56.40.

Plus Therapeutics Price Performance

The stock has a market capitalization of $25.13 million, a PE ratio of -1.59 and a beta of 1.40. The stock’s fifty day moving average is $4.61 and its 200-day moving average is $5.75.

Plus Therapeutics (NASDAQ:PSTV) last released its quarterly earnings data on Friday, May 15th. The company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.20). Plus Therapeutics had a negative net margin of 230.24% and a negative return on equity of 198.48%. The firm had revenue of $1.03 million during the quarter, compared to analysts’ expectations of $0.97 million. On average, analysts forecast that Plus Therapeutics, Inc. will post -3.76 EPS for the current year.

Institutional Trading of Plus Therapeutics

Several institutional investors have recently bought and sold shares of the business. Susquehanna International Group LLP purchased a new stake in shares of Plus Therapeutics in the third quarter valued at approximately $46,000. Jane Street Group LLC acquired a new stake in Plus Therapeutics in the 2nd quarter valued at $41,000. State Street Corp raised its position in Plus Therapeutics by 37.1% during the fourth quarter. State Street Corp now owns 468,893 shares of the company’s stock worth $240,000 after acquiring an additional 127,000 shares during the period. Scientech Research LLC acquired a new position in Plus Therapeutics during the third quarter worth $100,000. Finally, XTX Topco Ltd purchased a new position in Plus Therapeutics during the fourth quarter valued at $127,000. 3.28% of the stock is owned by institutional investors and hedge funds.

Plus Therapeutics Company Profile

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.